Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

J. Perlmutter · SciRah

Researcher profile · Semantic Scholar

J. Perlmutter

Share profile

J. Perlmutter — researcher profile on SciRah

h-index: 38
Works: 151
Citations: 16K

Most-cited papers

Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update.
K. Allison, M. Hammond, M. Dowsett, Shannon E McKernin +16 more
2020Journal of Clinical Oncology1,298 citations Open access
Semantic Scholar
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial.
R. Nanda, Minetta C. Liu, C. Yau, R. Shatsky +40 more
2020JAMA Oncology654 citations Open access
Semantic Scholar
Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline.
Benjamin D. Smith, J. Bellon, R. Blitzblau, G. Freedman +12 more
2018Practical Radiation Oncology585 citations
Semantic Scholar
Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer: A Randomized Clinical Trial.
E. Basch, D. Schrag, Sydney R Henson, Jennifer Jansen +25 more
2022Journal of the American Medical Association (JAMA)377 citations Open access
Semantic Scholar
Adaptive platform trials: definition, design, conduct and reporting considerations
D. Angus, B. Alexander, S. Berry, M. Buxton +45 more
2019Nature reviews. Drug discovery345 citations
Semantic Scholar
Current Landscape of Immunotherapy in Breast Cancer
S. Adams, M. Gatti-Mays, K. Kalinsky, L. Korde +18 more
2019JAMA Oncology339 citations Open access
Semantic Scholar
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
L. Pusztai, C. Yau, D. Wolf, Hyo S. Han +41 more
2021Cancer Cell311 citations Open access
Semantic Scholar
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.
K. Allison, M. Hammond, M. Dowsett, Shannon E McKernin +16 more
2020Archives of Pathology & Laboratory Medicine303 citations Open access
Semantic Scholar
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: predictive biomarkers across 10 cancer therapies
D. Wolf, C. Yau, J. Wulfkuhle, L. Brown-Swigart +29 more
2022Cancer Cell295 citations Open access
Semantic Scholar
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion.
D. Chakravarty, Amber M. Johnson, J. Sklar, N. Lindeman +14 more
2022Journal of Clinical Oncology225 citations Open access
Semantic Scholar
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.
D. Yee, A. DeMichele, C. Yau, C. Isaacs +75 more
2020JAMA Oncology210 citations Open access
Semantic Scholar
The clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy
M. Magbanua, L. Brown-Swigart, Ziad Ahmed, R. Sayaman +27 more
2023Cancer Cell169 citations Open access
Semantic Scholar
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0
S. Tolaney, E. Garrett-Mayer, J. White, V. Blinder +19 more
2021Journal of Clinical Oncology161 citations Open access
Semantic Scholar
Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update
S. Giordano, M. Franzoi, S. Temin, C. Anders +10 more
2022Journal of Clinical Oncology149 citations Open access
Semantic Scholar
Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study
P. Mangat, S. Halabi, S. Bruinooge, E. Garrett-Mayer +9 more
2018JCO Precision Oncology139 citations
Semantic Scholar
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer: An Analysis of Data From the I-SPY2 Randomized Clinical Trial.
W. Symmans, C. Yau, Yunni-Yi Chen, R. Balassanian +58 more
2021JAMA Oncology103 citations Open access
Semantic Scholar
MK-2206 and Standard Neoadjuvant Chemotherapy Improves Response in Patients With Human Epidermal Growth Factor Receptor 2-Positive and/or Hormone Receptor-Negative Breast Cancers in the I-SPY 2 Trial.
J. Chien, D. Tripathy, K. Albain, W. Symmans +45 more
2019Journal of Clinical Oncology97 citations Open access
Semantic Scholar
Management of Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Guideline Update
N. Ramakrishna, C. Anders, N. Lin, A. Morikawa +10 more
2022Journal of Clinical Oncology92 citations Open access
Semantic Scholar
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial
A. Clark, C. Yau, D. Wolf, E. Petricoin +47 more
2021Nature Communications73 citations Open access
Semantic Scholar
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care
N. Pennell, Melissa S. Dillmon, Laura A. Levit, E. Moushey +44 more
2020Journal of Clinical Oncology69 citations
Semantic Scholar
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomised I-SPY2.2 phase 2 trial
R. Shatsky, M. Trivedi, C. Yau, Rita Nanda +56 more
2024Nature Medicine55 citations Open access
Semantic Scholar
Pathologic complete response (pCR) rates for patients with HR+/HER2− high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial
L. Huppert, D. Wolf, C. Yau, L. Brown-Swigart +16 more
2024Annals of Oncology31 citations Open access
Semantic Scholar
Trial Design Considerations to Increase Older Adult Accrual to National Cancer Institute Clinical Trials.
J. Le-Rademacher, S. Mohile, Joseph M. Unger, M. Hudson +12 more
2022Journal of the National Cancer Institute. Monographs31 citations Open access
Semantic Scholar
Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy
L. Du, C. Yau, L. Brown-Swigart, R. Gould +28 more
2021Annals of Oncology31 citations Open access
Semantic Scholar
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
D. Yee, C. Isaacs, D. Wolf, C. Yau +51 more
2021npj Breast Cancer28 citations Open access
Semantic Scholar
Toronto Workshop on Late Recurrence in Estrogen Receptor–Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations
Ryan J. O. Dowling, K. Kalinsky, D. Hayes, F. Bidard +28 more
2019JNCI Cancer Spectrum26 citations Open access
Semantic Scholar
Digital symptom monitoring with patient-reported outcomes in community oncology practices: A U.S. national cluster randomized trial.
E. Basch, D. Schrag, Jennifer Jansen, Sydney R Henson +16 more
2021Journal of Clinical Oncology24 citations
Semantic Scholar
Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
J. Lang, A. Forero-Torres, D. Yee, C. Yau +45 more
2022npj Breast Cancer23 citations Open access
Semantic Scholar
Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials.
S. Hillman, A. Jatoi, C. Strand, J. Perlmutter +2 more
2023JAMA Oncology20 citations Open access
Semantic Scholar
Treatment Efficacy Score - continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials.
M. Marczyk, A. Mrukwa, C. Yau, D. Wolf +27 more
2022Annals of Oncology20 citations Open access
Semantic Scholar
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
Rosa I. Gallagher, J. Wulfkuhle, D. Wolf, L. Brown-Swigart +23 more
2023Cell Reports Medicine18 citations Open access
Semantic Scholar
Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions
Ryan J. O. Dowling, J. Sparano, P. Goodwin, F. Bidard +28 more
2019JNCI Cancer Spectrum18 citations Open access
Semantic Scholar
Datopotamab-deruxtecan in early stage breast cancer: the I-SPY2.2 sequential multiple assignment randomized phase 2 trial
Katia Khoury, J. Meisel, C. Yau, H. Rugo +53 more
2024Nature Medicine17 citations Open access
Semantic Scholar
Abstract CT011: Evaluation of durvalumab in combination with olaparib and paclitaxel in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
L. Pusztai, Hyo Han, C. Yau, D. Wolf +34 more
2020Tumor Biology17 citations
Semantic Scholar
Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL
D. Yee, A. Demichele, C. Isaacs, F. Symmans +75 more
201815 citations
Semantic Scholar
Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial
R. Leon-Ferre, K. Dimitroff, C. Yau, K. Giridhar +12 more
2025Breast Cancer Research14 citations Open access
Semantic Scholar
Neoadjuvant trebananib plus paclitaxel-based chemotherapy for stage II/III breast cancer in the adaptively randomized I-SPY2 trial — Efficacy and biomarker discovery
K. Albain, C. Yau, E. F. Petricoin, D. Wolf +45 more
2023Clinical Cancer Research14 citations Open access
Semantic Scholar
Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative
S. Evans, Dianne Paraoan, J. Perlmutter, Sudha R. Raman +2 more
2021Therapeutic Innovation and Regulatory Science14 citations Open access
Semantic Scholar
Abstract GS5-03: Evaluation of anti-PD-1 Cemiplimab plus anti-LAG-3 REGN3767 in early-stage, high-risk HER2-negative breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL
C. Isaacs, R. Nanda, J. Chien, M. Trivedi +31 more
2023Cancer Research13 citations
Semantic Scholar
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
H. Beckwith, Richard B. Schwab, C. Yau, E. Stringer-Reasor +28 more
2021Poster Spotlight Session Abstracts13 citations
Semantic Scholar
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
T. Marron, J. Luke, B. Hoffner, J. Perlmutter +6 more
2025Journal for ImmunoTherapy of Cancer11 citations Open access
Semantic Scholar
Author Correction: Adaptive platform trials: definition, design, conduct and reporting considerations
Derek C Angus, Brian M. Alexander, Scott M. Berry, M. Buxton +45 more
2019Nature reviews. Drug discovery11 citations Open access
Semantic Scholar
Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial
R. Mukhtar, K. Dimitroff, C. Yau, J. Chien +32 more
2025Annals of Surgical Oncology10 citations
Semantic Scholar
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer
Michael J. Campbell, D. Wolf, C. Yau, L. Brown-Swigart +22 more
2024Cell Reports Medicine10 citations Open access
Semantic Scholar
Cell-free DNA concentration as a biomarker of response and recurrence in HER2-negative breast cancer receiving neoadjuvant chemotherapy
M. Magbanua, Ziad Ahmed, R. Sayaman, Lamorna Brown Swigart +14 more
2024Clinical Cancer Research9 citations Open access
Semantic Scholar
Biomarkers predicting response to 5 immunotherapy arms in the neoadjuvant I-SPY2 trial for early-stage breast cancer (BC): Evaluation of immune subtyping in the response predictive subtypes (RPS).
D. Wolf, C. Yau, M. Campbell, A. Glas +15 more
2023Journal of Clinical Oncology9 citations Open access
Semantic Scholar
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer
H. Rugo, Mike Campbell, C. Yau, J. Chien +19 more
2024Breast Cancer Research and Treatment8 citations Open access
Semantic Scholar
Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Minetta C. Liu, P. Robinson, C. Yau, A. Wallace +30 more
20207 citations
Semantic Scholar
Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial
D. Wolf, C. Yau, M. Campbell, A. Glas +31 more
2025JCO Precision Oncology5 citations Open access
Semantic Scholar
Outcomes and clinicopathologic characteristics associated with disseminated tumor cells in bone marrow after neoadjuvant chemotherapy in high-risk early-stage breast cancer: the I-SPY SURMOUNT Study
M. Magbanua, L. J. van 't Veer, A. Clark, J. Chien +23 more
2023Breast Cancer Research and Treatment5 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

C. Yau×29
Invite
C. Yau — researcher profile on SciRah
W. Symmans×27
Invite
W. Symmans — researcher profile on SciRah
A. DeMichele×27
Invite
A. DeMichele — researcher profile on SciRah
H. Rugo×23
Invite
H. Rugo — researcher profile on SciRah

×20

Invite

J. Chien — researcher profile on SciRah

Invite

S. Asare — researcher profile on SciRah

Invite

N. Hylton — researcher profile on SciRah

Invite

D. Yee — researcher profile on SciRah

L. J. van 't Veer×17

Invite

L. J. van 't Veer — researcher profile on SciRah

Invite

R. Nanda — researcher profile on SciRah

Invite

C. Isaacs — researcher profile on SciRah

Invite

G. Hirst — researcher profile on SciRah